Table 1.
Single agent potency of pitavastatin and zoledronic acid in cell growth assays.
| IC50 (µM) | ||
|---|---|---|
| Cell line | Pitavastatin (n) | Zoledronic acid (n) |
| HOE | 0.69 ± 0.12 (6) | 57 ± 6 (5) |
| A2780 | 0.67 ± 0.34 (9) | 29 ± 4 (4) |
| CisA2780 | 14.0 ± 7.00 (9) | 36 ± 6 (8) |
| Cov-318 | 3.40 ± 1.40 (8) | 28 ± 2 (4) |
| Cov-362 | 3.10 ± 0.70 (8) | 42 ± 4 (4) |
| Ovcar-3 | 4.60 ± 0.90 (6) | 60 ± 4 (6) |
| Ovcar-4 | 5.20 ± 1.20 (4) | 51 ± 7 (4) |
| Ovcar-5 | 2.40 ± 1.30 (9) | 30 ± 6 (9) |
| Ovcar-8 | 0.40 ± 0.10 (4) | 21 ± 3 (4) |
| Igrov-1 | 1.60 ± 0.10 (9) | 43 ± 8 (7) |
| Skov-3 | 3.60 ± 1.00 (5) | 26 ± 5 (5) |
| Ovsaho | 0.69 ± 0.12 (5) | 44 ± 7 (3) |
Cells were exposed to a range of concentrations of pitavastatin or zoledronic acid for 72 hr, except for the slow growing cell lines Cov-318 and Cov-362 (120 hr). The numbers of surviving cells were estimated by statin with SRB. IC50s (mean ± S.D.) were calculated from the indicated number (n) of experiments.